Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use

Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-04, Vol.15 (4), p.e37441
Main Authors: Pacheco, Curtis S, White, Kevin M
Format: Article
Language:English
Subjects:
Allergy/Immunology
Asymptomatic
Biopsy
Case reports
Dermatitis
Dermatology
Etiology
Immunology
Inflammation
Monoclonal antibodies
Otolaryngology
Patients
Sinuses
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.37441